FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT05919264
Phase
PHASE1 / PHASE2
Sponsor
Parabilis Medicines, Inc.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • FOG-001
  • mFOLFOX-6
  • Nivolumab
  • Trifluridine/tipiracil
  • Bevacizumab
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Los Angeles, California, United States|34.05223,-118.24368
  • Palo Alto, California, United States|37.44188,-122.14302
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ and marrow function.
  • Additional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):
  • Diagnosis of treatment-refractory advanced/metastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor wi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →